Your browser doesn't support javascript.
loading
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
Yang, Hailing; Shu, Zhang; Jiang, Yongying; Mao, Weiqun; Pang, Lan; Redwood, Abena; Jeter-Jones, Sabrina L; Jennings, Nicholas B; Ornelas, Argentina; Zhou, Jinhua; Rodriguez-Aguayo, Cristian; Bartholomeusz, Geoffrey; Iles, LaKesla R; Zacharias, Niki M; Millward, Steven W; Lopez-Berestein, Gabriel; Le, Xiao-Feng; Ahmed, Ahmed A; Piwnica-Worms, Helen; Sood, Anil K; Bast, Robert C; Lu, Zhen.
Afiliação
  • Yang H; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Shu Z; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Jiang Y; Department of Geriatric Digestive Surgery, the Second Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Mao W; Institute for Applied Cancer Science, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Pang L; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Redwood A; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Jeter-Jones SL; Department of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Jennings NB; Department of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Ornelas A; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Zhou J; Cancer Systems Imaging, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Rodriguez-Aguayo C; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Bartholomeusz G; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Iles LR; Center for RNA Interference and Non-Coding RNA Cancer, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Zacharias NM; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Millward SW; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Lopez-Berestein G; Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Le XF; Cancer Systems Imaging, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Ahmed AA; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Piwnica-Worms H; Center for RNA Interference and Non-Coding RNA Cancer, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Sood AK; Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Bast RC; Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford, United Kingdom.
  • Lu Z; Nuffield Department of Women's & Reproductive Health, University of Oxford, Women's Centre, John Radcliffe Hospital, Oxford, United Kingdom.
Clin Cancer Res ; 25(18): 5702-5716, 2019 09 15.
Article em En | MEDLINE | ID: mdl-31391192
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama / Proteína Supressora de Tumor p53 / Paclitaxel / Resistencia a Medicamentos Antineoplásicos / Fosfofrutoquinase-2 Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama / Proteína Supressora de Tumor p53 / Paclitaxel / Resistencia a Medicamentos Antineoplásicos / Fosfofrutoquinase-2 Idioma: En Ano de publicação: 2019 Tipo de documento: Article